Sci Pharm. 2008; 76: 699–711.
Effect of Cilostazol in Alleviating Cardiovascular Complications through Regulation of Type 1 Plasminogen Activator Inhibitor and Transforming Growth Factor-β1 Overexpression in Experimental Rats
Rasha Hussieny MOHAMED
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zip code 44511, Zagazig, Egypt.
E-mail: rashahussieny@yahoo.com
Abstract
Cilostazol is a potent phosphodiesterase inhibitor; its major effects are prevention of platelet aggregation and dilation of blood vessels via an increase in tissue cAMP levels. This study examined the effect of cilostazol on serum cAMP, type 1 plasminogen activator inhibitor and transforming growth factor-β1 in relation to alleviating cardiovascular complications. This was achieved in rats through administration of L-NAME (0.1 mg/ml) for two weeks, and then followed by i.p. single dose of streptozotocin (65mg/kg). Rats were classified to three groups; normal rats, control diabetic hypertensive rats and the third group was treated with cilostazol (1.8 mg daily, orally) for six weeks. Cilostazol improved serum cAMP level and increased plasma NO concentration leading to dilation of blood vessels. In addition, cilostazol has beneficial lipoprotein-modifying effect. Cilostazol treatment confirmed the positive correlation between plasma PAI-1 activity and serum TGF-β1 which is beneficial in reducing the hazards of cardiovascular complications. Thus, cilostazol therapy provides a broad spectrum of effects in alleviating cardiovascular complications induced in experimental animals.
Keywords
Cilostazol phosphodiesterase inhibitor • Cyclic AMP • Plasminogen activator inhibitor-1 • Transforming growth factor-β1 • Cardiovascular complications
Received September 14th, 2008 | Accepted November 8th, 2008 | Published Online November 14th, 2008
